Adcock Ingram acquisition of NutriLida gets Competition Commission Approval
Adcock Ingram - Aug 4th 2011, 15:10
Adcock Ingram has been given unconditional approval by the Competition Commission to acquire Johannesburg-based supplements business NutriLida Healthcare. The acquisition, which comes into effect on 1 August 2011, will further strengthen Adcock Ingramâs position as the leader in the vitamins, minerals and supplements (VMS) market, while increasing its market share in the broader fast moving consumer goods (FMCG) market.
NutriLida is renowned for its market leading product range, which targets consumers and healthcare professionals. The NutriLida portfolio includes brands such as ProbiFlora, GynaGuard, ViralGuard, ArthroGuard and Natrodale.
Commenting on the acquisition, Dr Jonathan Louw, CEO of Adcock Ingram, said: âNutriLida has strong brands in several niche market segments. This acquisition, now that it is approved, will enable Adcock Ingram to move further into categories adjacent to our current business and to increase our visibility in the growing self-medication segment.â
Adcock Ingram has grown its presence in the supplements category in recent years. In the previous financial year, over-the-counter product growth was partly driven by supplements and energy products in the FMCG channel. The company already has a strong presence in the tonics market with household brands such as BioplusÂŽ, Vita-thionÂŽ and LivitonÂŽ.
According to Dr Louw, the South African VMS market has shown substantial growth over the last few years, primarily due to access, availability, an emerging middle class and the increase in proactive health management and self-medication by consumers.
Referring to plans by the Medicines Control Council to introduce regulation around complementary medicines, Dr Louw said: âAdcock Ingram welcomes the plans by the Medicines Control Council to start regulating complementary medicines. As a pharmaceutical company we adhere to the industry standards and therefore support the MCCâs taking control of what has been until now an unregulated arena.â
Double blow for Adcock suitor
03/12/2013 - 08:00
Johannesburg - A Chilean group's $1.2bn (R12.6bn) bid for drugmaker Adcock Ingram [JSE:AIP] was challenged on two fronts on Monday, as a group led by Bidvest [JSE:BVT] sought nearly a third of Adcock's shares and launched a court action against the bid.
Adcock leads JSE higher
18/11/2013 - 09:26
Johannesburg - South African shares put in a second straight day of gains on Friday with drugs maker Adcock in focus after Chile's CFR Pharmaceuticals formally bid $1.2bn to acquire it.
R13bn Adcock deal faces threat
12/11/2013 - 09:39
Johannesburg - Chile's CFR on Monday threatened to pull out its R13.48bn (at Monday's rand/dollar exchange rate) deal to buy drug maker Adcock Ingram if it does not win support from the state pension fund that ranks as Adcock's biggest shareholder.
âActis planning Adcock bidâ
14/08/2013 - 08:41
Johannesburg - Actis LLP, a London-based private-equity firm, has proposed an offer for Adcock Ingram Holdings Ltd. to rival a bid from Chilean drugmaker CFR Pharmaceuticals SA, two people familiar with the matter said.
PIC wants Adcock to stay in local hands
23/07/2013 - 08:56
Johannesburg - The top shareholder in Adcock Ingram said it would prefer a local buyer for the country's second-biggest drug maker over a $1.3bn bid from Chile's CFR Pharmaceutical.